RA Capital’s managing partner Peter Kolchinsky has authored two books which delve into biotech company creation and how society benefits – and should derive value from – the fruits of those companies’ labor.

The Great American Drug Deal

The Great American Drug Deal examines the healthcare landscape through the lens of the Biotech Social Contract, including the government's role in inventing drugs, direct-to-consumer advertising, the opioid crisis, the price-jacking of old drugs, and the impact on America of lower drug costs in other countries.


The Entrepreneur’s Guide to a Biotech Startup

If you are considering starting your own biotech company, you will appreciate the wealth of practical information packed into The Entrepreneur’s Guide to a Biotech Startup. This free 100-page eBook is based on personal interviews with entrepreneurs, investors, attorneys, and other professionals who understand biotech venture creation and are eager to share their insights.


Terms and Conditions


Before accessing these resources, the reader must review and acknowledge the following terms and conditions

By clicking “I Agree”, you acknowledge the following terms and conditions.

Publications are provided for informational purposes only and do not constitute an offer to sell, a solicitation to buy, or a recommendation for any security, nor do they constitute an offer or endorsement of RA Capital's investment advisory or other services by RA Capital Management (“RA Capital”). The content of the publications neither constitutes investment advice nor offers any opinion with respect to the suitability of any security. Accounts managed by RA Capital may invest in certain companies referenced in the publications; however, RA Capital makes no guarantees as to accuracy or completeness of views expressed in the publications. Views expressed in the publications are subject to change, and may have become unreliable for various reasons, including changes in market conditions or economic circumstances. Any disclosures as to RA Capital Management is subject to change and is only valid as of the date the statement was made. Any references, either general or specific, to securities and/or issuers are for illustrative purposes only and are not intended to be, and should not be interpreted as, advice or recommendations to purchase, continue to hold, or sell such securities. Certain current and prior investments may be highlighted in order to provide additional information regarding RA Capital’s investment strategy, the types of investments it pursues, and anticipated exit strategies. By accessing the publications, the reader agrees that he/she will not copy, reproduce, republish, upload, post, transmit, alter, or distribute the publications in any way that is inconsistent with the purposes for which they are offered, without the prior written consent of RA Capital.


This disclaimer is in addition to all disclaimers found on the RA Capital website.